What was keytruda's first fda approved cancer indication?

What was Keytruda’s first FDA-approved cancer use?

Keytruda (pembrolizumab) received its first FDA approval in September 2014 for unresectable or metastatic melanoma. The approval was for patients with disease progression following ipilimumab (or, if they couldn’t tolerate ipilimumab, after another prior therapy). [1]

Was it approved for melanoma before other cancers?

Yes. Keytruda’s initial FDA approval was specifically for melanoma, and later approvals expanded it to additional cancer types. [1]

Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s093lbl.pdf